Dr. Dirk Weber

Bis 2025, Executive Director, Regional Medical Lead Hematology, Europe Medical Affairs, BeOne Medicines Ltd., Switzerland
Basel, Schweiz

Fähigkeiten und Kenntnisse

Medical Affairs Leadership
Product Launch Excellence
Hematology
MD with extensive Pharmaceutical Industry experien
Oncology experience is expansive with Merck Serono
Worked extensively in early and late-stage Clinica
Excellent regulatory filing and launch experience
led a submission team and extensive experience in
Clinical development strategy
Oncology
Rare Disease
Evidence Generation
KOL Engagement
Strategic Leadership
Cross-functional leadership
Scientific Communications
Publication Planning
Lifecycle Management
Medical excellence
Market Access collaboration
Patient Advocacy Engagement
Organizational Development
Alliance management
Business Development
Digital strategy
Scientific advisory board
Management
Entrepreneurship
Extended leadership experience gained by leading c
Strong managerial skills by delivering projects wi
Excellent communication skills with capability to
Innovative Mind-set
responsible

Werdegang

Berufserfahrung von Dirk Weber

  • 6 Jahre und 2 Monate, Nov. 2019 - Dez. 2025

    Executive Director, Regional Medical Lead Hematology, Europe Medical Affairs

    BeOne Medicines Ltd., Switzerland

    • Led regional medical & digital strategy for hematology-oncology portfolio across Europe • Enabled successful launch of BTKi zanubrutinib across multiple indications (CLL, WM, MCL, MZL) • Prepared and implemented integrated evidence plan (RWE, Registries, Phase 4, IIT) • Developed global compassionate use and patient expanded access program • Established and led regional KOL Engagement and Communication Plan • Led preparation of HTA/JCA submission and regional evidence strategy for BCL2i sonrotoclax

  • 3 Jahre und 11 Monate, Dez. 2015 - Okt. 2019

    CMO & Co-Founder

    Cellestia Biotech AG (Basel / Lausane)

    Privately held spin-off company from EPFL Lausanne with compound CB-103, a First-in-Class oral NOTCH signalling inhibitor indicated for patients with leukemias, lymphomas and solid tumors. • Co-foundation and successful built of biotech company with advancing first-in-class NOTCH inhibitor (CB-103) from preclinical through clinical development planning and FDA IND approval • Delivered first-in-human clinical study approval and initiation

  • 7 Jahre und 7 Monate, März 2012 - Sep. 2019

    Chief Medical Officer & Co-Founder

    Aurealis Pharma AG (Basel & Kuopio/Finnland)

    - Co-Founder of company in 2012 - Chief Medical Officer - Member of the Board of Directors - Biopharmaceutical Company engaged in developing innovative treatments for chronic wounds - Responsible for Development Strategy and Planning

  • 2 Jahre und 4 Monate, März 2013 - Juni 2015

    Medical Affairs Head/Medical Director Oncology (Emerging Markets)

    Takeda Pharmaceuticals International

    I was responsible for the Medical Affairs group Emerging Markets and as Medical Director for all medical affairs activities for 4 oncology products. Responsible for hemato-oncology products (Hodgkin Lymphoma, NHL, PTCL, Multiple Myeloma) - responsible for oncology products (ovarian cancer, CRPC, gastrointestinal cancer) - responsible for all pre-launch activities and preparations for launch - 6 MDs & 5 Consultants reporting to me

  • 5 Jahre und 6 Monate, Sep. 2007 - Feb. 2013

    Global Clinical Program Head

    Novartis Pharma GmbH

    - Responsible for Clinical Development Plan and its execution. - Responsible for submission preparations for a product for treatment of Ovarian Cancer

  • 4 Jahre und 9 Monate, Jan. 2003 - Sep. 2007

    Clinical Team Leader

    Merck Serono

    - Global responsibility for the execution of the Clinical Development Plan in various cancer indications.

  • 2 Jahre und 1 Monat, Jan. 2001 - Jan. 2003

    Group Leader Research&Development

    Ivonex GmbH Kiel

    - responsible for preclinical development of a blood test to detect disseminated tumor cells in blood. - responsible for transfer of blood test from preclinics into clinical development.

Ausbildung von Dirk Weber

  • 2 Jahre, Jan. 1999 - Dez. 2000

    Medicine

    Georgetwon University

    Humanmedizin

  • 3 Jahre, Jan. 1994 - Dez. 1996

    Medicine

    Kuopio University

    Humanmedizin

  • 9 Jahre, Jan. 1992 - Dez. 2000

    Medicine

    Christian-Albrechts-Universität zu Kiel / University of Kiel

    Oncology

Sprachen

  • Deutsch

    C2 (Verhandlungssicher / Muttersprachlich)

  • Englisch

    C1 (Fließend)

  • Finnisch

    A1-A2 (Grundkenntnisse)

XING – Das Jobs-Netzwerk

  • Über eine Million Jobs

    Entdecke mit XING genau den Job, der wirklich zu Dir passt.

  • Persönliche Job-Angebote

    Lass Dich finden von Arbeitgebern und über 20.000 Recruiter·innen.

  • 21 Mio. Mitglieder

    Knüpf neue Kontakte und erhalte Impulse für ein besseres Job-Leben.

  • Kostenlos profitieren

    Schon als Basis-Mitglied kannst Du Deine Job-Suche deutlich optimieren.

21 Mio. XING Mitglieder, von A bis Z